Highlights from our recent research

With the majority of large corporate DB plans in surplus territory, we discuss strategies for preserving that surplus and deploying excess funds..
We examine recent real-world commercial health insurance claims experience for CAR-T therapies, comparing treatment costs to benchmarks based on wholesale acquisition cost.

We review the value of alignment for Namibia's (re)insurers and how far NSAP 104 supports it, and give some practical steps.